Oil control and repairing composition and skin care product using the same

Abstract

The present invention discloses a skin care product of an oil control and repair composition and its application, and relates to the technical field of skin care products. The oil control and repair composition is composed of the following ingredients: dipeptide-1530000-45000ppm, oligopeptide-11000-2000ppm, dianthin 0.002-0.01wt%, Tibetan mushroom extract 0.005-0.015wt%, PEG-40 hydrogenated castor oil 1-2wt%, hexanediol 0.2-1wt%, pentanediol 1-5wt%, cellulose 0.1-0.5wt%, pH regulator to adjust the pH of the composition to 4-7, and the remainder is water. The oil control and repair composition of the present invention has long-term stability, is used in skin care products, has oil control, soothing, repairing effects and is safe and non-toxic, and the oil control and repair composition can complete the preparation of skin care products by simply mixing with an auxiliary agent.

Description

Technical Field

[0001] The present invention relates to the technical field of skin care products, and in particular to an oil-controlling and repairing composition and a skin care product using the same. Background Art

[0002] Oily skin refers to excessive secretion of oil on the surface of the skin, which makes the skin greasy and shiny. Excessive sebum secretion in oily skin can easily cause skin problems such as enlarged pores, clogged pores, dull skin, acne inflammation, and poor antibacterial ability.

[0003] Excessive secretion of sebaceous glands is closely related to the content of dihydrotestosterone in the sebaceous glands. Dihydrotestosterone binds to the receptors in the sebaceous gland cells, which promotes the proliferation of sebaceous gland cells and stimulates sebum secretion. Excessive sebum secretion will prevent the excess sebaceous gland secretions from being metabolized in time, causing oil to accumulate in the hair follicles and expand the pores, resulting in enlarged pores (according to the skin analyzer, any size larger than 0.02mm is detected 2 The round opening of the hair follicle). Enlarged pores will also increase sebum secretion, increase the loss of skin water, and have a high proportion of unsaturated fatty acids, making the skin oily on the outside and dry on the inside. When the epidermis is taken away too much water by the external environment, the sebaceous glands of the skin will secrete more oil to form a barrier to protect the moisture of the epidermis in order to prevent the skin from being invaded by the external environment. Therefore, if you want to control oil, you need to do a good job of "water and oil balance" to better solve the problems of oily skin and oil beans. In addition, some studies have shown that an imbalance in skin microorganisms can cause the skin to be too dry or too oily, thereby affecting the secretion of oil. Skin microecological balance refers to the balance between the microbial community on the surface of the skin (such as bacteria, fungi, viruses, etc.) and the host skin. This balance is very important for maintaining skin health. The relationship between skin microecological balance and oil control is closely related.

[0004] Therefore, oily skin care requires targeted skin care ingredients to maintain the balance of water and oil, maintain the balance of skin microecology, and provide precise skin care from the inside out.

[0005] Existing studies have shown that dipeptide-15 can target chloride ion channels and promote Cl - Influx, regulates intracellular ion balance, downregulates IL-1α to improve abnormal keratinization, thereby shrinking pores and increasing skin moisture content. Oligopeptide-1 is a synthetic peptide composed of glycine, histidine and lysine. It acts on the dermis and can significantly enhance cell vitality, promote epidermal stem cell secretion and cell proliferation. Therefore, dipeptide-15 and oligopeptide-1 are often used in skin care products or cosmetics.

[0006] For example, patent CN111035609A discloses a small molecule polypeptide eye essence, including an oligopeptide mixture, a small molecule polypeptide mixture, a stem cell mixture, deep-sea collagen powder and an adjuvant; the oligopeptide mixture is composed of oligopeptide-1, oligopeptide-3, oligopeptide-4 and oligopeptide-5; the small molecule polypeptide mixture is composed of tripeptide-1 copper, palmitoyl pentapeptide-4, acetyl tetrapeptide-15, dipeptide-2, acetyl hexapeptide-8, tripeptide-1, nonapeptide-1, palmitoyl tetrapeptide-7 and carnosine; the eye essence is prepared by compounding a plurality of small molecule polypeptides and stem cell mixtures, which has the effects of inhibiting melanin in the eye skin, increasing skin elasticity, and anti-wrinkle and skin firming.

[0007] CN108403457A also discloses a facial mask liquid for repairing red blood streaks, comprising 16-24 parts of protein growth factor, 2-4 parts of licorice chalcone A, 30-50 parts of lactobacillus / mung bean seed extract / sodium glutamate fermentation product filtrate, 6-10 parts of vitamin C ethyl ether, and vitamin A. 8-12 parts, vitamin B24-6 parts, ceramide 9-15 parts, niacinamide 3-5 parts, rose hydrosol 10-20 parts, lanolin 15-23 parts, arginine 4-8 parts, butylene glycol 12-16 parts, D-panthenol 7-11 parts, folic acid 0.1-0.3 parts, hyaluronic acid 24-32 parts, tea polyphenols 0.5-3.5 parts, thickener 1-14 parts, deionized water 80-100 parts; protein growth factors include oligopeptide-120-28%, oligopeptide-210-14%, oligopeptide-318-22%, oligopeptide-526-46%, palmitoyl tripeptide-86-10%; it has the effects of replenishing intercellular matrix, rebuilding stratum corneum, promoting fibroblast proliferation, repairing damaged epidermal barrier, and curing red blood streaks.

[0008] CN115487100A discloses a cosmetic composition with the effects of controlling oil and refining pores, comprising 0.1-2% dipeptide-15, 0.05-3% butyl avocado oleate, 0.1-1% hydroxystearic acid and 0.01-2% chlorella extract, which has the effects of controlling the oil content of the skin and refining pores.

[0009] However, the following problems still exist when small molecule peptides are used in skin care products for oily skin: 1) The stability of the contents of skin care products is difficult to maintain, and physical and chemical performance problems such as precipitation and discoloration are prone to occur; 2) Small molecule peptides are unstable in skin care products and easily decompose, which reduces the peptide content and weakens the efficacy of skin care products; 3) The solubility of small molecule peptides is limited, and their own oil control, soothing and repair effects are limited. The efficacy of skin care products cannot be improved by increasing the content of small molecule peptides, and too high a content is more likely to cause stability problems. Summary of the invention

[0010] In view of the above problems, the purpose of the present invention is to invent an oil control and repair composition that can be used as a raw material for skin care products. The raw material oil control and repair composition has long-term stability, synergizes with small molecule peptides to enhance oil control and repair effects, and the skin care product can be prepared by simply mixing with auxiliary agents.

[0011] The long-term stability of cosmetic contents, the compatibility of formula raw materials and the continuity of raw material quality have always been urgent problems to be solved in cosmetic research and development. The present invention studies the properties and active ingredient content of small molecule peptide skin care raw materials under different conditions, and prepares a long-term stable and effective prescription system through screening, as follows.

[0012] According to the formulations shown in Tables 1-3, the compositions of Experiments 1-18 were prepared.

[0013] Table 1 Composition formula of Experiments 1-6

[0014]

[0015] CO40: PEG-40 hydrogenated castor oil; ZEN: ZEN thickener; Tibetan mushroom extract: Tibetan mushroom extract Kefi rCC

[0016] Table 2 Composition formula of experiments 7-13

[0017]

[0018] Table 3 Composition formula of Experiments 14-18

[0019]

[0020]

[0021] Cellulose: Sodium carboxymethyl cellulose

[0022] The compositions of Experiments 1-6 and 8-18 were tested according to the following steps:

[0023] 1) pH test and adjustment were performed on the prepared compositions of Experiments 1-6 and 8-18, and properties were observed; among them, the properties (including after pH adjustment) were clear and transparent with no / slight precipitation, which was considered acceptable;

[0024] 2) Taking another composition with qualified properties in step 1) and standing it at room temperature for 7 days, and detecting the content of dipeptide-15 and oligopeptide-1 in the composition by high performance liquid chromatography; the content of dipeptide-15 and oligopeptide-1 is qualified if the content decreases by no more than 20%;

[0025] 3) Separately take three groups of samples of the qualified compositions in step 1), place them in 40°C (high temperature), 25°C (normal temperature) and 4°C (low temperature) environments, and observe their stability within three months; if the test results of high temperature, normal temperature and low temperature are all no discoloration and no / slight precipitation, the stability is qualified;

[0026] 4) The samples with qualified stability in step 3) are tested for the content of dipeptide-15 and oligopeptide-1, and the samples are qualified if the content of dipeptide-15 and oligopeptide-1 decreases by no more than 20%.

[0027] The composition of Experiment 7 was tested according to the following steps:

[0028] The composition of Experiment 7 was spray dried; after storage for 7 days, it was prepared into an aqueous solution of the initial volume, and the contents of dipeptide-15 and oligopeptide-1 were detected.

[0029] The test results of the compositions of Experiments 1-6 and 8-18 are shown in Table 4 below.

[0030] Table 4 Test results of compositions of experiments 1-6, 8-18

[0031]

[0032]

[0033] The samples after the stability test of the composition in Experiment 5 were as follows Figure 1 As shown; the samples after the stability test of the experimental 6 composition are as follows Figure 2 As shown; the samples after the stability test of the experimental 9 composition are as follows Figure 3 As shown; the sample after the stability test of the composition of Experiment 10 is as follows Figure 4 As shown; the sample after the stability test of Experiment 11 composition is as follows Figure 5 As shown; the sample after the stability test of Experiment 12 composition is as follows Figure 6 As shown; the sample after the stability test of Experiment 13 composition is as follows Figure 7 As shown; the sample after the stability test of Experiment 14 composition is as follows Figure 8 As shown; the sample after the stability test of Experiment 15 composition is as follows Fig. 9 As shown; the sample after the stability test of Experiment 17 composition is as follows Fig.10 As shown; the sample after the stability test of Experiment 18 composition is as follows Fig.11 shown.

[0034] The test results of the composition of Experiment 7: the theoretical content of dipeptide-15 is 96.15%, and the theoretical content of oligopeptide-1 is 2.23%; the actual content of dipeptide-15 is 89.39%, and the actual content of oligopeptide-1 is 3.60%.

[0035] The test results of the above Experiments 1-18 compositions are summarized in Table 5 below.

[0036] Table 5 Test results of compositions of experiments 1-18

[0037]

[0038]

[0039] In summary, the following Scheme I and Scheme II meet the formulation screening indicators, and Scheme I and Scheme II are shown in Table 6.

[0040] Table 6 Formulas of Scheme I and Scheme II

[0041]

[0042] Kefir CC, a fermented product of Tibetan mushroom, is a yellow liquid. Batch number: 230003.

[0043] The compositions of Scheme I and Scheme II were subjected to cytotoxicity test, lipid content test, cytokine test, and cell migration test.

[0044] 1. Materials and Methods

[0045] 1. Main Reagents

[0046] Phosphate buffered saline (PBS), Shanghai Solebold; MTT, Yuanye Biotechnology; dimethyl sulfoxide (DMSO), Tianjin Damao; high glucose medium 1×DMEM, Gibco; fetal bovine serum (FBS), Gibco; mouse IL-1α ELISA kits were purchased from Xinbosheng; EGF and dexamethasone, Solebold; human keratinocytes HaCaT and mouse macrophages RAW264.7 were purchased from the Kunming Cell Bank of the Chinese Academy of Sciences; human sebaceous gland cells SZ95 were purchased from Wuhan Pronocell Life Science Technology Co., Ltd.

[0047] 2. Main instruments

[0048] Carbon dioxide incubator, Shanghai Yiheng; clean bench, Sujing; biological inverted microscope, Guangzhou Mingmei; microplate reader, Shanghai Shanpu.

[0049] 2. Detection Experiment Method

[0050] 1. Cell proliferation activity / toxicity detection method

[0051] a) Take a bottle of cells in good condition in the exponential growth phase, add 0.25% trypsin digestion solution, digest to make the adherent cells fall off, and count 1-4×10 5 / mL to prepare a cell suspension.

[0052] b) Take an appropriate amount of cell suspension and inoculate it into a 96-well plate, and culture it in a constant temperature CO2 incubator for 24 hours.

[0053] c) Change the medium, add the test drug, and culture for 48 hours.

[0054] d) Add MTT reagent to the 96-well plate and react in an incubator for 4 hours.

[0055] e) Aspirate the supernatant, add DMSO, and shake on a plate shaker for 5 min.

[0056] f) After 5 min, the reference OD values ​​at 490 nm and 630 nm were read using a microplate reader, and the cell viability was calculated.

[0057] Cell viability = (OD of the drug-treated well - OD of the zero-adjusted well) / (OD of the control well - OD of the zero-adjusted well) × 100%.

[0058] 2. Oil content test

[0059] a) Take a bottle of SZ-95 cells in good condition in the exponential growth phase, add 0.25% trypsin digestion solution, digest to make the adherent cells fall off, and count 1-4×10 5 / mL to prepare a cell suspension.

[0060] b) The cell suspension was inoculated onto a 96-well plate and cultured in a constant temperature CO2 incubator for 24 h.

[0061] c) Except for the normal group, which was added with PBS, FFA (including linoleic acid and other fatty acids) was added to each well of the remaining wells. While inducing modeling, the test drugs were added and cultured in a constant temperature CO2 incubator for 48 hours.

[0062] d) Aspirate the culture medium and proceed according to the instructions of the Oil Red O staining kit.

[0063] 3. Cytokine IL-1α test

[0064] a) Take cells in good exponential growth phase, digest them, inoculate them into 12-well plates, and culture them for 24 hours.

[0065] b) The complete medium in the wells was aspirated, and PBS was added for starvation treatment for 3 hours. The blank control group was added with complete medium, the model group was added with LPS and complete medium, and the sample group was added with LPS, complete medium and diluted samples, and cultured for 48 hours.

[0066] c) Aspirate the cell supernatant culture medium, centrifuge and take the supernatant. Perform the test according to the ELISA kit instructions.

[0067] 4. Cell Migration Test

[0068] a) Take a bottle of cells in good exponential growth phase, add 0.25% trypsin to digest, make a cell suspension, inoculate on a 24-well plate, and culture in a constant temperature CO2 incubator for 24 hours.

[0069] b) Change the medium and draw a cross in the well with a yellow pipette tip. Add complete medium and sample to the drug group; add complete medium and PBS / 0.5% DMSO to the blank control group. Then place in a constant temperature CO2 incubator for 24 hours.

[0070] c) After 24 hours of incubation, take photos and observe using an inverted biological microscope.

[0071] 5. Statistical Analysis

[0072] All experiments were repeated at least three times according to the parallel design principle, and the experimental data were expressed as mean ± SD, and the T test was used for data comparison and analysis. Compared with the Control, P < 0.05 was significant; P < 0.01 was significantly significant; P < 0.001 was very significantly significant.

[0073] 3. Experimental Results

[0074] 1. Cytotoxicity Assay

[0075] The cytotoxicity (activity) was taken as the reference ratio of the control group. Six dosing concentrations of the composition samples of Scheme I and Scheme II were set from high to low: 1ppm, 10ppm, 20ppm, 50ppm, 100ppm, and 200ppm (based on the total amount of core components). Cytotoxicity detection experiments were carried out on SZ95 cells, RAW264.7 cells, and HaCaT cells. The higher the cell activity, the greater the value, and vice versa. The cell activity was significantly lower than 90% as the cytotoxicity threshold.

[0076] The test results of the effect of the composition of Scheme I on the activity of SZ95 cells are as follows Fig.12 As shown;

[0077] The test results of the effect of the composition of Scheme I on the activity of RAW264.7 cells are as follows Fig.13 As shown;

[0078] The test results of the effect of the composition of scheme I on the activity of HaCaT cells are as follows Fig.14 As shown;

[0079] The test results of the effect of the composition of Scheme II on the activity of SZ95 cells are as follows Fig.15 As shown;

[0080] The test results of the effect of the composition of Scheme II on the activity of RAW264.7 cells are as follows Fig.16 As shown;

[0081] The test results of the effect of the composition of scheme II on the activity of HaCaT cells are as follows Fig.17 shown.

[0082] Compared with the Control group, *P<0.05, **P<0.01, ***P<0.001.

[0083] The test results showed that the compositions of Scheme I and Scheme II had no obvious cytotoxicity to SZ95 cells, RAW264.7 cells and HaCaT cells at a concentration of 1 ppm-200 ppm (based on the total amount of core components).

[0084] 2. Oil content test

[0085] Oil Red O is a fat-soluble dye that is highly soluble in fat. The principle of its staining is that Oil Red O can specifically adsorb neutral triglycerides, lipids and lipoproteins in tissues and cells to stain fat. The composition samples of Scheme I and Scheme II were set to three dosing concentrations of 50ppm, 100ppm, and 200ppm (based on the content of core components) from low to high (the concentrations of 50ppm, 100ppm, and 200ppm correspond to the raw material addition amounts of 0.12%, 0.24%, and 0.48%, respectively), SZ95 cells (human sebaceous gland cells) were selected, and FFA (containing linoleic acid and other fatty acids) was used for modeling. Simvastatin was used as a positive reference to compare and verify the oil control efficacy of the composition of Scheme I and Scheme II. The smaller the value, the better the oil control effect.

[0086] The results of the test on the effect of the combination of Scheme I and Scheme II on the lipid production of SZ95 cells are as follows Fig.18 As shown, ###P<0.001 compared with the Control group; *P<0.05, **P<0.01, ***P<0.001 compared with the FFA group.

[0087] The test pictures of the effects of FFA, simvastatin, Scheme I and Scheme II on lipid production in SZ95 cells are shown in Fig.19 shown.

[0088] The test results show that compared with the FFA control group, the composition of Scheme I can significantly reduce the production of oil and inhibit oil production at a concentration of 50ppm-200ppm, and has an oil control effect; the composition of Scheme II also has a certain oil control effect at a concentration of 50ppm-200ppm, but it is significantly inferior to the composition of Scheme I.

[0089] The test results of the compositions of Scheme I and Scheme II are shown in Table 7. Fig.18The test results shown are: relative oil inhibition rate = (FFA relative oil generation - 100%) / (FFA relative oil generation - composition relative oil generation).

[0090] Table 7 Cytotoxicity and oil content test results of Scheme I and Scheme II compositions

[0091]

[0092] Note: *P<0.05, *P<0.01, ***P<0.001

[0093] As can be seen from Table 7, the compositions of Scheme I and Scheme II are both safe and non-cytotoxic; from the perspective of the relative inhibition rate of oil, Scheme I has the best oil control effect at an addition amount of 200ppm. Therefore, Scheme I was selected for the next step of the soothing effect-IL-1α cytokine test and the repair effect-cell migration test.

[0094] 3. Cytokine testing

[0095] Pro-inflammatory cytokines are involved in normal inflammatory and immune responses. Excessive secretion of inflammatory cytokines by skin immune cells will promote the oil secretion of sebaceous gland cells, leading to excessive oil secretion. The stronger the anti-inflammatory ability of the sample, the lower the content of pro-inflammatory cytokines; the weaker the anti-inflammatory ability of the sample, the higher the content of pro-inflammatory cytokines.

[0096] IL-1α can stimulate the sebaceous glands to secrete oil. When the IL-1a in the skin increases, the secretion of the sebaceous glands will also increase accordingly, causing the skin to become greasy. In addition, IL-1α can promote the proliferation of sebaceous gland cells and the expression of lipid synthase, further increasing oil secretion.

[0097] RAW264.7 cells (mouse mononuclear macrophage leukemia cells) were selected, LPS (lipopolysaccharide) was used as the modeling agent, and DEX (dexamethasone) was used as the positive reference. The soothing effects of the samples with three concentrations of 50ppm, 100ppm, and 200ppm (calculated in terms of core component content) of the composition of Scheme I were compared and verified from high to low (the concentrations of 50ppm, 100ppm, and 200ppm corresponded to raw material addition amounts of 0.12%, 0.24%, and 0.48%, respectively). The smaller the value, the better the soothing effect.

[0098] Test results such as Fig. 20 As shown, compared with the Control group, ###P<0.001; compared with the LPS control group, *P<0.05, **P<0.01, ***P<0.001. The test results of cytokine IL-1α showed that compared with the LPS control group, the composition of Scheme I significantly reduced the IL-1α content at the tested concentration and had the effect of inhibiting the secretion of IL-1α.

[0099] 4. Cell Migration Test

[0100] Cell migration is one of the basic functions of normal cells, a physiological process of normal growth and development of the body, and a common form of movement of living cells. Cell migration is similar to the skin wound healing process, so promoting cell migration has a positive effect on skin repair.

[0101] HaCaT cells (immortalized epidermal cells) were selected for the cell migration test. The Control group was used as the reference control and EGF as the positive reference. The repair efficacy of the samples with three concentrations of 50ppm, 100ppm, and 200ppm (calculated in terms of core component content) of the composition of Scheme I was compared and verified from high to low (the concentrations of 50ppm, 100ppm, and 200ppm corresponded to raw material addition amounts of 0.12%, 0.24%, and 0.48%, respectively); the better the cell migration promoting effect, the smaller the scratch distance.

[0102] The scratch marks of each group before and after drug administration are as follows Fig.21 As shown in Figure 2, the scratch healing rate is Fig. 22 shown.

[0103] The test results showed that compared with the Control group, the composition of Scheme I at a concentration of 50ppm-200ppm can significantly shorten the scratch distance of HaCaT cells, promote the migration of HaCaT cells, and has a skin repair effect.

[0104] IV. Conclusion

[0105] 1. Cytotoxicity test:

[0106] Scheme I showed no obvious cytotoxicity to SZ95 cells, RAW264.7 cells and HaCaT cells at concentrations of 1ppm-200ppm.

[0107] Scheme II showed no obvious cytotoxicity to SZ95 cells, RAW264.7 cells and HaCaT cells at concentrations of 1ppm-200ppm.

[0108] 2. Grease content test:

[0109] Scheme I can significantly reduce the production of oil at a concentration of 50ppm-200ppm, indicating that Scheme I can significantly inhibit the production of oil and has an oil control effect.

[0110] Scheme II can significantly reduce the production of oily hair at a concentration of 100ppm-200ppm, indicating that Scheme II can significantly inhibit oil production and has an oil control effect.

[0111] 3. Cytokine test:

[0112] Scheme I can significantly reduce the IL-1α content at a concentration of 50ppm-200ppm, indicating that Scheme I has the effect of inhibiting IL-1α secretion.

[0113] 4. Cell migration test:

[0114] Scheme I can significantly shorten the scratch distance of HaCaT cells at a concentration of 50ppm-200ppm, promote the migration of HaCaT cells, and has a skin repair effect.

[0115] In summary, Plan I has the effects of oil control and repair.

[0116] Based on the above experiments and test results, the present invention provides an oil control and repair composition, which is composed of the following ingredients:

[0117]

[0118] pH regulator, for adjusting the pH of the composition to 4-7,

[0119] The balance is water.

[0120] Preferably, the oil control and repair composition consists of the following ingredients:

[0121]

[0122] pH regulator, for adjusting the pH of the composition to 4-7,

[0123] The balance is water.

[0124] Preferably, the pH adjuster is citric acid.

[0125] Preferably, the oil control and repair composition consists of the following ingredients:

[0126]

[0127] Citric acid, to adjust the pH of the composition to 5-6.5,

[0128] The balance is water.

[0129] The preparation method of the above-mentioned oil control and repair composition comprises the following steps:

[0130] S1: Disperse cellulose with water to form a mixed solution A; disperse oleanol and PEG-40 hydrogenated castor oil with water to form a mixed solution B; disperse dipeptide-15 and oligopeptide-1 with water to form a mixed solution C;

[0131] S2: adding the mixed solution A, hexylene glycol and pentanediol into water, dispersing and mixing to obtain a mixed phase I;

[0132] S3: adding mixed solution B, Tibetan mushroom extract and mixed solution C to mixed phase I and dissolving them to obtain mixed phase II;

[0133] S4: Measure the pH of the mixed phase II, and adjust the pH with a pH adjuster to obtain an oil-controlling and repairing composition.

[0134] Preferably, in step S2, the temperature of the dispersion mixing is ≤40°C, more preferably 15-30°C.

[0135] Preferably, in step S3, the temperature of mixed dissolution is ≤40°C, more preferably 15-30°C.

[0136] Preferably, the water is purified water sterilized at 85-90°C for 10-20 min.

[0137] The present invention also provides a skin care product with oil control and repairing effects, comprising the above-mentioned oil control and repairing composition.

[0138] Preferably, the content of the oil control and repair composition in the skin care product is 0.1-0.5 wt %.

[0139] Preferably, the skin care product with oil control and repairing effect also includes a cosmetic matrix to form skin care product dosage forms of different dosage forms. The skin care product dosage form can be cream, lotion, essence, skin care gel, lotion or other cosmetic products for skin care.

[0140] Preferably, the skin care product with oil control and repairing effects is composed of the following ingredients: 0.1-0.5wt% oil control and repairing composition, 6-12wt% hexylene glycol and / or pentylene glycol, 0.2-1.5wt% carbomer, 0.05-1wt% PEG-40 hydrogenated castor oil and / or hydroxyethyl cellulose, 0.1-0.5wt% sodium hyaluronate, 0.01-0.3wt% methyl hydroxybenzoate, citric acid / sodium citrate to adjust pH 4-7, and the balance is water.

[0141] The preparation method is as follows: according to the proportion, hexylene glycol and / or pentylene glycol, carbomer, PEG-40 hydrogenated castor oil and / or hydroxyethyl cellulose, sodium hyaluronate, and methyl hydroxybenzoate are added into water and mixed evenly, then citric acid / sodium citrate is added to adjust the pH to 4-7, and then the oil control and repair composition is added and mixed evenly.

[0142] The oil control and repair composition of the present invention has long-term stability, is used in skin care products, has oil control, soothing and repairing effects, and is safe and non-toxic. The oil control and repair composition can be used to prepare skin care products by simply mixing with an auxiliary agent. BRIEF DESCRIPTION OF THE DRAWINGS

[0143] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the following briefly introduces the drawings required for use in the description of the embodiments. Obviously, the drawings described below are some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying any creative work.

[0144] Figure 1 This is a sample picture after the stability test of Experiment 5 composition.

[0145] Figure 2 This is a sample picture after the stability test of the composition in Experiment 6.

[0146] Figure 3 This is a sample picture after the stability test of the composition in Experiment 9.

[0147] Figure 4 This is a sample picture after the stability test of the composition in Experiment 10.

[0148] Figure 5 This is a sample picture after the stability test of the composition in Experiment 11.

[0149] Figure 6 This is a sample picture of the composition of Experiment 12 after stability testing.

[0150] Figure 7 This is a sample picture after the stability test of the composition in Experiment 13.

[0151] Figure 8 This is a sample picture after the stability test of Experiment 14 composition.

[0152] Fig. 9 This is a sample picture after the stability test of Experiment 15 composition.

[0153] Fig.10 This is a sample picture after the stability test of Experiment 17 composition.

[0154] Fig.11 This is a sample picture after the stability test of the composition in Experiment 18.

[0155] Fig.12 The results are the test results of the effect of the composition of Scheme I on the activity of SZ95 cells.

[0156] Fig.13 The results are the test results of the effect of the composition of Scheme I on the activity of RAW264.7 cells.

[0157] Fig.14 The results are the test results of the effect of the composition of Scheme I on the activity of HaCaT cells.

[0158] Fig.15The results are the test results of the effect of the composition of Scheme II on the activity of SZ95 cells.

[0159] Fig.16 The results are the test results of the effect of the composition of Scheme II on the activity of RAW264.7 cells.

[0160] Fig.17 The results are the test results of the effect of the composition of Scheme II on the activity of HaCaT cells.

[0161] Fig.18 The results are of the effects of the compositions of Scheme I and Scheme II on lipid production in SZ95 cells.

[0162] Fig.19 The test pictures show the effects of the compositions of Scheme I and Scheme II on lipid production in SZ95 cells.

[0163] Fig. 20 The results are of the test on the effect of the composition of Scheme I on the secretion of IL-1α in RAW264.7 cells.

[0164] Fig.21 The figures show the test results of the effects of the compositions of Scheme I at different concentrations on the migration of HaCaT cells.

[0165] Fig. 22 The figure shows the results of the scratch test of the effect of the composition of Scheme I at different concentrations on the migration of HaCaT cells. DETAILED DESCRIPTION

[0166] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0167] It should be understood that when used in this specification and the appended claims, the terms "include" and "comprises" indicate the presence of described features, integers, steps, operations, elements and / or components, but do not exclude the presence or addition of one or more other features, integers, steps, operations, elements, components and / or combinations thereof.

[0168] It is also to be understood that the terminology used in the description of the present invention herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the present invention.

[0169] It should be further understood that the term "and / or" used in the present description and the appended claims refers to any and all possible combinations of one or more of the associated listed items, and includes these combinations.

[0170] The preparation method of the oil control and repair composition of the present invention comprises the following steps:

[0171] Sterilize the required purified water at 85-90℃ for 10-20min;

[0172] Dispersing cellulose with purified water to form a mixed solution A; dispersing oleanol and PEG-40 hydrogenated castor oil with purified water to form a mixed solution B; and dispersing dipeptide-15 and oligopeptide-1 with purified water to form a mixed solution C;

[0173] Add mixed solution A, hexylene glycol and pentanediol into purified water at 15-30° C., disperse and mix to obtain mixed phase I;

[0174] Add mixed solution B, Tibetan mushroom extract and mixed solution C to mixed phase I, control the temperature at 15-30° C. to mix and dissolve, and obtain mixed phase II;

[0175] The pH of the mixed phase II is measured, and the pH is adjusted with a pH adjuster to obtain an oil-controlling and repairing composition.

[0176] Specifically, the preparation method of the oil control and repair composition of the following Examples 1-7 is as follows:

[0177] Sterilize the required purified water at 90℃ for 15min;

[0178] Dispersing cellulose with purified water to form a mixed solution A; dispersing oleanol and PEG-40 hydrogenated castor oil with purified water to form a mixed solution B; and dispersing dipeptide-15 and oligopeptide-1 with purified water to form a mixed solution C;

[0179] Add mixed solution A, hexylene glycol and pentanediol into purified water at 25° C., disperse and mix to obtain mixed phase I;

[0180] Add mixed solution B, Tibetan mushroom extract and mixed solution C to mixed phase I, control the temperature at 25° C. to mix and dissolve, and obtain mixed phase II;

[0181] The pH of the mixed phase II was measured and adjusted with citric acid to obtain an oil-controlling and repairing composition.

[0182] The oil control and repair compositions of Examples 1-7 were prepared using the formulations of Examples 1-7 shown in Table 8 below and the preparation method of Example 1.

[0183] Table 8 Formula of the oil control and repair composition of Examples 1-7

[0184] Formulation / Example Example 1 Example 2 Example 3 Example 4 Example 5 Example 6 Example 7 Dipeptide-15 40000ppm 30000ppm 45000ppm 45000ppm 30000ppm 42000ppm 35000ppm Oligopeptide-1 1500ppm 1000ppm 2000ppm 1000ppm 2000ppm 1800ppm 1200ppm Caryophyllene (wt%) 0.005 0.002 0.01 0.005 0.005 0.007 0.003 Tibetan mushroom extract (wt%) 0.01 0.005 0.015 0.01 0.01 0.008 0.012 CO40(wt%) 1.7 1 2 1.7 1.7 1.7 1.7 Hexanediol (wt%) 0.5 0.2 1 0.5 0.5 0.5 0.5 Pentylene glycol (wt%) 3 1 5 3 3 3 3 Cellulose (wt%) 0.2 0.1 0.5 0.2 0.2 0.2 0.2 Citric acid Adjust pH to 5.5 Adjust pH to 7 Adjust pH to 4 Adjust pH to 4.8 Adjust pH to 6.4 Adjust pH to 5.5 Adjust pH to 5.5 water TO100% TO100% TO100% TO100% TO100% TO100% TO100%

[0185] CO40 is PEG-40 hydrogenated castor oil; Tibetan mushroom extract is selected from Tibetan mushroom extract Kefi r CC

[0186] The compositions of Examples 1-7 were tested according to the following steps:

[0187] 1) Observe the properties of the oil-control and repairing compositions of Examples 1-7; the properties are qualified if the properties are clear and transparent and there is no or slight precipitation;

[0188] 2) Another composition of Examples 1-7 with qualified properties was placed at room temperature for 7 days, and the content of dipeptide-15 and oligopeptide-1 in the composition was detected by high performance liquid chromatography; the content of dipeptide-15 and oligopeptide-1 was qualified if the content of dipeptide-15 and oligopeptide-1 decreased by no more than 20%;

[0189] 3) Separately take the compositions that have passed the content test in step 2) and divide them into three groups of samples, place them in 40°C (high temperature), 25°C (normal temperature) and 4°C (low temperature) environments respectively, and observe their stability within 1 month; if the high temperature, normal temperature and low temperature test results are all no discoloration and no / slight precipitation, the stability is qualified.

[0190] The test results are shown in Table 9 below.

[0191] Table 9 Test results of oil control and repairing compositions of Examples 1-7

[0192]

[0193]

[0194] During the development of the present invention, in order to further determine the content range in which dipeptide-15 and oligopeptide-1 can stably exist in the oil control and repair composition of the present invention, based on the formula of Example 1, the shapes and stability of the compositions of Comparative Examples 1-5 as shown in Table 10 were investigated.

[0195] Table 10 Formula of oil control and repair composition of comparative examples 1-5

[0196] Formula / Comparative Example Example 1 Comparative Example 1 Comparative Example 2 Comparative Example 3 Comparative Example 4 Comparative Example 5 Dipeptide-15 40000ppm 48000ppm 50000ppm 40000ppm 40000ppm 48000ppm Oligopeptide-1 1500ppm 1500ppm 1500ppm 2500ppm 3000ppm 2500ppm Caryophyllene (wt%) 0.005 0.01 0.01 0.01 0.01 0.01 Tibetan mushroom extract (wt%) 0.01 0.015 0.015 0.015 0.015 0.015 CO40(wt%) 1.7 2 2 2 2 2 Hexanediol (wt%) 0.5 1 1 1 1 1 Pentylene glycol (wt%) 3 5 5 5 5 5 Cellulose (wt%) 0.2 0.5 0.5 0.5 0.5 0.5 water TO100% TO100% TO100% TO100% TO100% TO100% Citric acid Adjust pH to 5.5 Adjust pH to 4-7 Adjust pH to 4-7 Adjust pH to 4-7 Adjust pH to 4-7 Adjust pH to 4-7

[0197] Note: Adjusting pH to 4-7 means attempting to adjust the pH of the composition within the range of pH 4-7 so that the composition can achieve qualified properties.

[0198] The compositions of Comparative Examples 1-5 were tested according to the following steps:

[0199] 1) Observe the properties of the compositions of Comparative Examples 1-5; the compositions that are clear and transparent and have no or slight precipitation are considered qualified;

[0200] 2) Three groups of samples were taken from the qualified compositions of Comparative Examples 1-5, respectively, and placed in 40°C (high temperature), 25°C (normal temperature) and 4°C (low temperature) environments to observe their stability within 1 month; the high temperature, normal temperature and low temperature test results showed no discoloration and no / slight precipitation, indicating qualified stability.

[0201] The test results are shown in Table 11 below.

[0202] Table 11 Test results of oil control and repairing compositions of Examples 1-7

[0203]

[0204] Furthermore, the oil control and repairing composition of Example 1 is used to prepare skin care products with oil control and repairing effects as shown in Examples 8-11 in Table 12 below. The preparation method is as follows: according to the ratio, hexylene glycol and / or pentylene glycol, carbomer, PEG-40 hydrogenated castor oil and / or hydroxyethyl cellulose, sodium hyaluronate, and methyl hydroxybenzoate are added to water and mixed evenly, then citric acid / sodium citrate is added to adjust the pH to 4-7, and then the oil control and repairing composition is added and mixed evenly.

[0205] Table 12 Formulations of skin care products of Examples 8-11

[0206]

[0207]

[0208] The skin care products of Examples 8-11 were divided into three groups of samples, which were placed in 40°C (high temperature), 25°C (normal temperature) and 4°C (low temperature) environments for 1 month, and then the dipeptide-15 and oligopeptide-1 contents were tested. The dipeptide-15 and oligopeptide-1 contents were qualified if they decreased by no more than 20%. The test results are shown in Table 13.

[0209] Table 13 Skin care product test results of Examples 8-11

[0210]

[0211] It can be seen from the results in Table 13 that the cosmetic matrix used in the skin care products of Examples 8-11 is compatible with the oil control and repair composition of Example 1 and will not cause an excessive decrease in the content of dipeptide-15 and oligopeptide-1.

[0212] Furthermore, during the research and development process of the present invention, based on the formula of Example 1, attempts were made to replace the oligopeptide-1 in the formula of Example 1 with oligopeptide-2, oligopeptide-3, oligopeptide-4, oligopeptide-5 and their combinations. The results showed that the composition also had the problems of incompatibility of composition ingredients, poor stability and / or easy reduction of peptide content.

[0213] The above is only a specific embodiment of the present invention, but the protection scope of the present invention is not limited thereto. Any technician familiar with the technical field can easily think of various equivalent modifications or replacements within the technical scope disclosed by the present invention, and these modifications or replacements should be included in the protection scope of the present invention. Therefore, the protection scope of the present invention shall be based on the protection scope of the claims.

Claims

1. An oil control and repair composition, characterized in that: It is composed of the following ingredients: pH regulator, for adjusting the pH of the composition to 4-7, The balance is water.

2. The oil control and repairing composition according to claim 1, characterized in that: It is composed of the following ingredients: pH regulator, for adjusting the pH of the composition to 4-7, The balance is water.

3. The oil control and repairing composition according to claim 2, characterized in that: The pH regulator is citric acid.

4. The oil control and repairing composition according to claim 3, characterized in that: It is composed of the following ingredients: Citric acid, to adjust the pH of the composition to 5-6.5, The balance is water.

5. The method for preparing the oil control and repairing composition according to any one of claims 1 to 4, characterized in that: The following steps are involved: S1: Disperse cellulose with water to form a mixed solution A; disperse oleanol and PEG-40 hydrogenated castor oil with water to form a mixed solution B; disperse dipeptide-15 and oligopeptide-1 with water to form a mixed solution C; S2: adding the mixed solution A, hexylene glycol and pentanediol into water, dispersing and mixing to obtain a mixed phase I; S3: adding mixed solution B, Tibetan mushroom extract and mixed solution C to mixed phase I and dissolving them to obtain mixed phase II; S4: Measure the pH of the mixed phase II, and adjust the pH with a pH adjuster to obtain an oil-controlling and repairing composition.

6. The method for preparing the oil control and repairing composition according to claim 5, characterized in that: In the step S2, the temperature of the dispersion mixing is ≤40°C.

7. The method for preparing the oil control and repairing composition according to claim 5, characterized in that: In step S3, the temperature of mixed dissolution is ≤40°C.

8. A skin care product with oil control and repairing effects, characterized in that: The invention comprises the oil control and repairing composition as claimed in any one of claims 1 to 4.

9. The skin care product with oil control and repairing effect according to claim 8, characterized in that: The content of the oil control and repair composition in the skin care product is 0.1-0.5wt%.

10. The skin care product with oil control and repairing effect according to claim 9, characterized in that: The invention is composed of the following ingredients: 0.1-0.5wt% oil control and repairing composition, 6-12wt% hexylene glycol and / or pentylene glycol, 0.2-1.5wt% carbomer, 0.05-1wt% PEG-40 hydrogenated castor oil and / or hydroxyethyl cellulose, 0.1-0.5wt% sodium hyaluronate, 0.01-0.3wt% methyl hydroxybenzoate, citric acid / sodium citrate to adjust pH 4-7, and the balance is water.

Images